chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).
Company profile
Ticker
CDXC
Exchange
Website
CEO
Robert Fried
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CODY RESOURCES, INC.
SEC CIK
Corporate docs
Subsidiaries
ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...
IRS number
262940963
CDXC stock data
Latest filings (excl ownership)
8-K
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
424B5
Prospectus supplement for primary offering
6 Jul 23
EFFECT
Notice of effectiveness
6 Jul 23
CORRESP
Correspondence with SEC
30 Jun 23
UPLOAD
Letter from SEC
27 Jun 23
S-8
Registration of securities for employees
22 Jun 23
S-3
Shelf registration
22 Jun 23
Transcripts
CDXC
Earnings call transcript
2023 Q2
9 Aug 23
CDXC
Earnings call transcript
2023 Q1
10 May 23
CDXC
Earnings call transcript
2022 Q4
8 Mar 23
CDXC
Earnings call transcript
2022 Q3
2 Nov 22
CDXC
Earnings call transcript
2022 Q2
11 Aug 22
CDXC
Earnings call transcript
2022 Q1
13 May 22
CDXC
Earnings call transcript
2021 Q4
10 Mar 22
CDXC
Earnings call transcript
2021 Q3
4 Nov 21
CDXC
Earnings call transcript
2021 Q2
4 Aug 21
CDXC
Earnings call transcript
2021 Q1
9 May 21
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 26.77 mm | 26.77 mm | 26.77 mm | 26.77 mm | 26.77 mm | 26.77 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 382.33 k | 572.92 k | (no burn) | (no burn) |
| Cash used (since last report) | n/a | n/a | 840.89 k | 1.26 mm | n/a | n/a |
| Cash remaining | n/a | n/a | 25.93 mm | 25.51 mm | n/a | n/a |
| Runway (months of cash) | n/a | n/a | 67.8 | 44.5 | n/a | n/a |
Institutional ownership, Q2 2023
62.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 61 |
| Opened positions | 8 |
| Closed positions | 10 |
| Increased positions | 11 |
| Reduced positions | 13 |
| 13F shares | Current |
|---|---|
| Total value | 12.59 bn |
| Total shares | 47.08 mm |
| Total puts | 2.10 k |
| Total calls | 7.00 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Champion River Ventures | 7.94 mm | $9.77 mm |
| Pioneer Step | 6.92 mm | $8.51 mm |
| Shing Li Ka | 6.50 mm | $11.44 mm |
| Hoi Shuen Solina Holly Chau | 5.96 mm | $38.73 mm |
| Societe des Produits Nestle | 3.82 mm | $5.53 mm |
| Li Ka Shing | 3.47 mm | $12.97 mm |
| Vanguard | 3.04 mm | $4.78 bn |
| Tieton Capital Management | 2.57 mm | $4.04 mm |
| ICONIQ Capital | 1.30 mm | $2.04 bn |
| Phillip MD Frost Et Al | 1.23 mm | $11.82 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Dec 23 | Brianna Gerber | Common Stock | Buy | Acquire P | No | No | 1.41 | 5,000 | 7.05 k | 27,436 |
| 6 Sep 23 | Champion River Ventures | Common Stock | Buy | Acquire P | Yes | No | 0 | 3,467,778 | 0.00 | 11,408,715 |
| 12 Aug 23 | Brianna Gerber | Common Stock | Option exercise | Acquire M | No | No | 0 | 22,436 | 0.00 | 22,436 |
| 12 Aug 23 | Brianna Gerber | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 22,436 | 0.00 | 44,872 |
| 15 Jun 23 | Frank L Jaksch Jr | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 20,000 | 33.40 k | 20,000 |
| 15 Jun 23 | Ann Cohen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 20,000 | 33.40 k | 20,000 |
News
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside, Supplementation Induces A Potent NAD+ Response And Is Associated With Mild Improvement In Parkinson's Disease
30 Nov 23
ChromaDex New Published Phase II Clinical Study Demonstrates That Supplementation With Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up To Fourfold, Improving Motor Coordination And Eye Movement In Ataxia Telangiectasia Patients
15 Nov 23
ChromaDex: Q3 Earnings Insights
8 Nov 23
ChromaDex Q3 2023 Gaap EPS $(0.01) Beats $(0.03) Estimate, Sales $19.50M Miss $20.25M Estimate
8 Nov 23
Earnings Scheduled For November 8, 2023
8 Nov 23
Press releases
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
30 Nov 23
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
15 Nov 23
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
9 Nov 23
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
8 Nov 23
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
1 Nov 23